SCHEMBL3523706

SCHEMBL3523706

CCOC(=O)C(C)OCc1cc2cc(C(F)(F)F)ccc2n1S(=O)(=O)c1cc(OC)ccc1OC

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARG P37231 8/20 0.51
PPARA Q07869 7/20 0.49
PPARD Q03181 6/20 0.49
TSHR P16473 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
KMT2A Q03164 1/20 0.40
IDH1 O75874 1/20 0.36
GAA P10253 2/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
RECQL P46063 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HTR6 P50406 1/20 0.35
CACNA1D Q01668 1/20 0.35
TACR1 P25103 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3525321 0.91 PPARG (0.56) PPARGPPARAPPARDTSHRSMN1; SMN2
SCHEMBL3527564 0.87 PPARG (0.47) PPARGPPARAPPARDTSHRSMN1; SMN2
SCHEMBL3527536 0.82 PPARG (0.57) PPARGPPARAPPARDTSHRSMN1; SMN2
SCHEMBL3529433 0.82 PPARG (0.59) PPARGPPARAPPARD
SCHEMBL3526416 0.81 PPARG (0.54) PPARGPPARAPPARDTSHRSMN1; SMN2
SCHEMBL3525500 0.78 PPARG (0.51) PPARGPPARAPPARDTSHRMEN1
SCHEMBL3528748 0.76 PPARG (0.44) PPARGPPARAPPARDSMN1; SMN2LMNA
SCHEMBL3527627 0.75 PPARG (0.50) PPARGPPARAPPARDTSHRSMN1; SMN2
SCHEMBL3527997 0.75 PPARG (0.56) PPARGPPARAPPARDSMN1; SMN2MEN1
SCHEMBL3527579 0.73 PPARG (0.45) PPARGPPARAPPARDALDH1A1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP PPARG 1018/4885PPARA 847/4885PPARD 677/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG PPARG 3/4885PPARA 2/4885PPARD 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.